{"id":3325,"date":"2026-09-21T09:00:00","date_gmt":"2026-09-21T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3325"},"modified":"2026-09-21T20:18:21","modified_gmt":"2026-09-22T00:18:21","slug":"caplyta-reduces-acute-bipolar-mania-in-phase-3","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3325","title":{"rendered":"Caplyta Reduces Acute Bipolar Mania in Phase 3"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Johnson and Johnson<\/p>\n

Event Type<\/strong><\/p>\n

Phase 3 Clinical Readout<\/p>\n

Modality<\/strong><\/p>\n

Oral Atypical Antipsychotic (Small Molecule)<\/p>\n

Asset<\/strong><\/p>\n

Caplyta (Lumateperone)<\/p>\n

Target<\/strong><\/p>\n

Serotonin 5-HT2A Antagonism and Dopamine D2 Partial Agonism (Proposed)<\/p>\n

Disease Area<\/strong><\/p>\n

Bipolar I Disorder, Acute Mania<\/p>\n

Summary<\/h4>\n

Johnson and Johnson reported that once-daily lumateperone 42 mg reduced acute manic symptoms in bipolar I disorder in the randomized three-week Study 451. The placebo-adjusted Young Mania Rating Scale improvement was 4.8 points at Week 3 with an effect size of 0.69 and p<0.0001. Response occurred in 45.8% versus 20.9% on placebo. A second pivotal study remains under analysis, and mania is not an approved indication.<\/p>\n

The double-blind trial enrolled adults experiencing manic episodes with or without mixed features. Significant YMRS separation was reported by Day 3 and sustained through Week 3. Clinical Global Impression Severity also improved by 0.5 points versus placebo. The rapid onset is relevant for a condition that can require hospitalization, but hospitalization, remission, suicidality, and longer relapse-prevention outcomes were not disclosed.<\/p>\n

Reported treatment-related adverse events occurring in at least 5% and at twice placebo were dry mouth and nausea, each 7.9%, versus 3.4% and 2.3%. The company described discontinuation as low and safety as consistent with the established profile. Full serious adverse event, sedation, metabolic, extrapyramidal, and mixed-feature subgroup data are needed for comparative benefit-risk assessment.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that lumateperone can extend from bipolar depression into acute mania, potentially simplifying longitudinal treatment. The effect size, early separation, and response difference support meaningful short-term activity. Against this, one positive study does not establish the full development package, and acute mania treatment decisions depend heavily on sedation, agitation control, metabolic burden, and practical use in hospitalized populations.<\/p>\n

A second interpretation is that the mechanism and existing commercial footprint reduce launch risk if approved. Lumateperone is already used in schizophrenia, bipolar depression, and adjunctive major depression. Yet the mania market includes inexpensive generics with extensive experience, so commercial differentiation requires reproducible efficacy, favorable tolerability, and clear labeling. The second pivotal study is critical because discordance would weaken both regulatory and positioning arguments.<\/p>\n

Company and Product Background<\/h4>\n

Caplyta is the brand name for lumateperone, an oral atypical antipsychotic. Its precise mechanism is not established; proposed activity includes serotonin 5-HT2A antagonism and dopamine D2 partial agonism. It is approved in adults for schizophrenia, bipolar depression, and adjunctive treatment of major depressive disorder, but not for acute bipolar mania.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Primary efficacy: 4.8-point placebo-adjusted YMRS reduction at Week 3, effect size 0.69, p<0.0001.<\/li>\n
  • Response: 45.8% versus 20.9% placebo, with statistically significant separation by Day 3.<\/li>\n
  • Evidence gap: full safety table, remission, hospitalization data, and the second pivotal study (Study 452) remain pending.<\/li>\n
  • Regulatory status: Caplyta is not currently approved for bipolar mania.<\/li>\n
  • Upgrade path: a concordant Study 452, remission and functional data, detailed low discontinuation and metabolic findings, and an accepted supplemental filing.<\/li>\n
  • Falsifier: replication failure, clinically important sedation or activation, or an agency request for additional trials.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    The disclosed effect size and response difference make this a high-importance positive clinical signal. Direction is not contingent on company tone; the randomized trial met a prespecified primary endpoint. Interpretation remains moderate until Study 452 and the complete safety package are available, because regulatory and clinical displacement claims require replication and comparative context.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal importance is high given the large effect size and rapid onset in a condition that can require hospitalization. Direction is positive based on the statistically significant primary endpoint. Confidence in the underlying facts is high, from a primary corporate disclosure with numeric randomized results and trial identification, while confidence in interpretation is moderate because the second pivotal study and full safety dataset are pending.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Johnson and Johnson reported that once-daily lumateperone 42 mg reduced acute manic symptoms in bipolar I disorder in the randomized three-week Study 451. The placebo-adjusted Young Mania Rating Scale improvement was 4.8 points at…<\/p>\n","protected":false},"author":1,"featured_media":3340,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[825,824,826],"class_list":["post-3325","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-bipolar-disorder","tag-johnson-and-johnson","tag-lumateperone"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3325","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3325"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3325\/revisions"}],"predecessor-version":[{"id":3347,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3325\/revisions\/3347"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3340"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3325"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3325"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3325"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}